Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Castle Biosciences Inc’s stock clocked out at $38.25, up 0.39% from its previous closing price of $38.1. In other words, the price has increased by $0.39 from its previous closing price. On the day, 0.51 million shares were traded. CSTL stock price reached its highest trading level at $38.88 during the session, while it also had its lowest trading level at $37.83.
Ratios:
To gain a deeper understanding of CSTL’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.82. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.47. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $25.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $54.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $59.Stephens initiated its Overweight rating on January 07, 2022, with a $59 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when MAETZOLD DEREK J sold 1,339 shares for $40.03 per share. The transaction valued at 53,600 led to the insider holds 37,547 shares of the business.
MAETZOLD DEREK J sold 2,678 shares of CSTL for $105,058 on Dec 02 ’25. The Pres. & Chief Exec. Officer now owns 38,886 shares after completing the transaction at $39.23 per share. On Nov 26 ’25, another insider, MAETZOLD DEREK J, who serves as the Pres. & Chief Exec. Officer of the company, sold 4,258 shares for $40.09 each. As a result, the insider received 170,703 and left with 41,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CSTL now has a Market Capitalization of 1116466304 and an Enterprise Value of 877446784. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.25 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 2.554 whereas that against EBITDA is 112.076.
Stock Price History:
The Beta on a monthly basis for CSTL is 1.06, which has changed by 0.29240167 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, CSTL has reached a high of $40.61, while it has fallen to a 52-week low of $14.59. The 50-Day Moving Average of the stock is 27.82%, while the 200-Day Moving Average is calculated to be 72.11%.
Shares Statistics:
It appears that CSTL traded 397.15K shares on average per day over the past three months and 416960 shares per day over the past ten days. A total of 29.16M shares are outstanding, with a floating share count of 28.44M. Insiders hold about 2.55% of the company’s shares, while institutions hold 91.27% stake in the company. Shares short for CSTL as of 1763078400 were 1641694 with a Short Ratio of 4.13, compared to 1760486400 on 1608069. Therefore, it implies a Short% of Shares Outstanding of 1641694 and a Short% of Float of 6.43.
Earnings Estimates
The stock of Castle Biosciences Inc (CSTL) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.19 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$0.23 and -$1.22 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$1.38, with 7.0 analysts recommending between -$0.69 and -$2.05.
Revenue Estimates
In. The current quarter, 8 analysts expect revenue to total $76.22M. It ranges from a high estimate of $79.07M to a low estimate of $74.2M. As of. The current estimate, Castle Biosciences Inc’s year-ago sales were $86.31MFor the next quarter, 8 analysts are estimating revenue of $75.54M. There is a high estimate of $78.2M for the next quarter, whereas the lowest estimate is $73.7M.
A total of 8 analysts have provided revenue estimates for CSTL’s current fiscal year. The highest revenue estimate was $334.25M, while the lowest revenue estimate was $331.4M, resulting in an average revenue estimate of $333.03M. In the same quarter a year ago, actual revenue was $332.07MBased on 8 analysts’ estimates, the company’s revenue will be $329.43M in the next fiscal year. The high estimate is $337.51M and the low estimate is $319.7M.
